Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 4/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29593103 | 0.87 | SLC22A12 (0.32) | SLC22A12P2RX7MAPK1NPSR1MAPT | |
| SCHEMBL22379486 | 0.83 | LPL (0.34) | SLC22A12P2RX7MAPK1NPSR1KDM4E | |
| SCHEMBL2649862 | 0.82 | KDM4E (0.38) | KDM4EALDH1A1HPGD | |
| SCHEMBL14052907 | 0.81 | TDP1 (0.33) | NPSR1MAPTALDH1A1GAATDP1 | |
| SCHEMBL5264851 | 0.80 | EPHX2 (0.32) | — | |
| SCHEMBL31170340 | 0.79 | — | — | |
| SCHEMBL2662281 | 0.77 | RAB9A (0.37) | NPSR1MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL31698288 | 0.74 | P2RX7 (0.32) | P2RX7 | |
| SCHEMBL2648450 | 0.73 | BACE1 (0.32) | AR | |
| SCHEMBL31048086 | 0.72 | TSHR (0.37) | KDM4EALDH1A1HPGDAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12633548-B2 | Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells | LITRONIK BATTERIETECHNOLOGIE GMBH (DE) | 2026-05-19 | — | — | US | claimed |
| US-20220263102-A1 | ELIMINATING VOLTAGE DELAY AND STABILIZING IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS | LITRONIK BATTERIETECHNOLOGIE GMBH (DE) | 2022-08-18 | — | — | US | claimed |
| EP-3997748-A1 | ELIMINATION OF VOLTAGE DELAY AND STABILIZATION OF IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS | LITRONIK Batterietechnologie GmbH (DE) | 2022-05-18 | — | — | EP | claimed |
| US-12633548-B2 | Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells | LITRONIK BATTERIETECHNOLOGIE GMBH (DE) | 2026-05-19 | — | — | US | disclosed |
| US-20220263102-A1 | ELIMINATING VOLTAGE DELAY AND STABILIZING IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS | LITRONIK BATTERIETECHNOLOGIE GMBH (DE) | 2022-08-18 | — | — | US | disclosed |
| EP-3997748-A1 | ELIMINATION OF VOLTAGE DELAY AND STABILIZATION OF IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS | LITRONIK Batterietechnologie GmbH (DE) | 2022-05-18 | — | — | EP | disclosed |
| US-9133178-B2 | Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer'S disease | PROXIMAGEN LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20130310380-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | PROXIMAGEN LIMITED (GB) | 2013-11-21 | — | — | US | disclosed |
| EP-2632918-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | Proximagen Limited (GB) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012055942-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | PROXIMAGEN LIMITED (GB) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310380-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | CHRNA7, CHRNA10, CHRNA5 | SLC22A12 2958/4885P2RX7 45/4885MAPK1 2072/4885 |
| US-12633548-B2 | Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells | KCNN1, HCN4, KCNN2 | SLC22A12 723/4885P2RX7 1753/4885MAPK1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.